Personalized medicine. Closing the gap between knowledge and clinical practice

Autoimmunity Reviews

Volumn 15, Issue 8, 2016, Pages 833-842

  Anaya, Juan Manuel ^a   Duarte Rey, Carolina ^a   Sarmiento Monroy, Juan C ^a   Bardey, David ^b,c   Castiblanco, John ^a   Rojas Villarraga, Adriana ^a  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

^b UNIVERSIDAD DE LOS ANDES   (Colombia)

^c TOULOUSE SCHOOL OF ECONOMICS   (France)

Author keywords

Autoimmune ecology; Developing countries; Pharmacogenomics; Precision medicine; Rheumatoid arthritis; Type 1 diabetes

Indexed keywords

AUTOIMMUNE DISEASE; CLINICAL PRACTICE; DEVELOPING COUNTRY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW (TOPIC); AUTOIMMUNE DISEASES; HEALTH CARE DELIVERY; HUMAN GENOME; PREVENTIVE MEDICINE; PROCEDURES;

BIOLOGICAL MARKER;

AUTOIMMUNE DISEASES; BIOMARKERS; DELIVERY OF HEALTH CARE; DEVELOPING COUNTRIES; GENOME, HUMAN; HUMANS; PRECISION MEDICINE; PREVENTIVE MEDICINE;

EID: 84979266578     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.06.005     Document Type: Review

References (149)

1. [1] Ginsburg, G.S., Willard, H.F., Genomic and personalized medicine: foundations and applications. Transl Res 154 (2009), 277–287, 10.1016/j.trsl.2009.09.005.
2. [2] Hood, L., A personal journey of discovery: developing technology and changing biology. Annu Rev Anal Chem (Palo Alto Calif) 1 (2008), 1–43, 10.1146/annurev.anchem.1.031207.113113.
3. [3] Ehrlich, I., Becker, G., Mark Insur self-insurance, self-protection. J Polit Econ, 1972, 623–648.
4. [4] Cohen, J.T., Neumann, P.J., Weinstein, M.C., Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 358 (2008), 661–663, 10.1056/NEJMp0708558.
5. [5] Maciosek, M.V., Coffield, A.B., Edwards, N.M., Flottemesch, T.J., Goodman, M.J., Solberg, L.I., Priorities among effective clinical preventive services results of a systematic review and analysis. Am J Prev Med 31 (2006), 52–61, 10.1016/j.amepre.2006.03.012.
6. [6] Akhmetov, I., Bubnov, R.V., Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA J, 6, 2015, 19, 10.1186/s13167-015-0041-3.
7. [7] Rappaport, S.M., Implications of the exposome for exposure science. J Expo Sci Environ Epidemiol 21 (2011), 5–9, 10.1038/jes.2010.50.
8. [8] Ross, J.S., Ginsburg, G.S., The integration of molecular diagnostics with therapeutics. Am J Clin Pathol 119 (2003), 26–36, 10.1309/VMLL66Y5KHQ35KUE.
9. [9] Anaya, J.-M., Ramirez-Santana, C., Alzate, M.A., Molano-Gonzalez, N., Rojas-Villarraga, A., The autoimmune ecology. Front Immunol, 7, 2016, 139, 10.3389/FIMMU.2016.00139.
10. [10] Marincola, F.M., Sheikh, J.I., A road map to translational medicine in Qatar and a model for the world. J Transl Med, 10, 2012, 177, 10.1186/1479-5876-10-177.
11. [11] Tobón, G.J., Pers, J.-O., Cañas, C.A., Rojas-Villarraga, A., Youinou, P., Anaya, J.-M., Are autoimmune diseases predictable?. Autoimmun Rev, 2011, 10.1016/j.autrev.2011.10.004.
12. [12] Auffray, C., Charron, D., Hood, L., Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med, 2, 2010, 57, 10.1186/gm178.
13. [13] Khoury, M.J., Gwinn, M., Glasgow, R.E., Kramer, B., A population perspective on how personalized medicine can improve health. Am J Prev Med 42 (2012), 639–645, 10.1016/j.amepre.2012.02.012.A.
14. [14] Kondylakis, H., Kazantzaki, E., Koumakis, L., Genitsaridi, I., Marias, K., Gorini, A., et al. Development of interactive empowerment services in support of personalised medicine. Ecancermedicalscience, 8, 2014, 400, 10.3332/ecancer.2014.400.
15. [15] Discipulus Consortium, Roadmap for the digital patient. 2014.
16. [16] Shields R. Common Disease: Are Causative Alleles Common or Rare? n.d. doi: http://dx.doi.org/10.1371/journal.pbio.1001009.
17. [17] Joyner, M.J., Prendergast, F.G., Joyner, M.J., Chasing Mendel: five questions for personalized medicine. J Physiol 59211 (2014), 2381–2388, 10.1113/jphysiol.2014.272336.
18. [18] Anaya, J.M., Rojas-Villarraga, A., García-Carrasco, M., The autoimmune tautology: from polyautoimmunity and familial autoimmunity to the autoimmune genes. Autoimmune Dis 1 (2012), 2012–2014, 10.1155/2012/297193.
19. [19] Huizinga, T.W.J., Personalized medicine in rheumatoid arthritis: is the glass half full or half empty?. J Intern Med 277 (2015), 178–187, 10.1111/joim.12319.
20. [20] Zhang, X., Kuivenhoven, J.A., Groen, A.K., Forward individualized medicine from personal genomes to interactomes. Front Physiol 6 (2015), 1–11, 10.3389/fphys.2015.00364.
21. [21] Coote, J.H., Joyner, M.J., Is precision medicine the route to a healthy world?. Lancet, 385, 2015, 1617, 10.1016/S0140-6736(15)60786-3.
22. [22] Cárdenas-Roldán, J., Rojas-Villarraga, A., Anaya, J.-M., How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med, 11, 2013, 73, 10.1186/1741-7015-11-73.
23. [23] Goulielmos, G.N., Zervou, M.I., Myrthianou, E., Burska, A., Niewold, T.B., Ponchel, F., Genetic data: the new challenge of personalized medicine, insights for rheumatoid arthritis patients. Gene, 2016, 10.1016/j.gene.2016.02.004.
24. [24] van Aken, J., Heimans, L., Gillet-van Dongen, H., Visser, K., Ronday, H.K., Speyer, I., et al. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis 73 (2014), 396–400, 10.1136/annrheumdis-2012-202967.
25. [25] van Nies, J.A.B., de Jong, Z., van der Helm-van Mil, A.H.M., Knevel, R., Le Cessie, S., Huizinga, T.W.J., Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology 49 (2010), 2210–2216, 10.1093/rheumatology/keq250.
26. [26] Gerlag, D.M., Raza, K., van Baarsen, L.G.M., Brouwer, E., Buckley, C.D., Burmester, G.R., et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the study Group for Risk Factors for rheumatoid arthritis. Ann Rheum Dis 71 (2012), 638–641, 10.1136/annrheumdis-2011-200990.
27. [27] Mankia, K., Emery, P., Review: preclinical rheumatoid arthritis: progress toward prevention. Arthritis Rheum 68 (2016), 779–788, 10.1002/art.39603.
28. [28] Umićević Mirkov, M., Coenen, M.J.H., Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine. Pharmacogenomics 14 (2013), 425–444, 10.2217/pgs.13.22.
29. [29] Burska, A.N., Roget, K., Blits, M., Soto Gomez, L., van de Loo, F., Hazelwood, L.D., et al. Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics J 14 (2014), 93–106, 10.1038/tpj.2013.48.
30. [30] Glocker, M.O., Guthke, R., Kekow, J., Thiesen, H.-J., Rheumatoid arthritis, a complex multifactorial disease: on the way toward individualized medicine. Med Res Rev 26 (2006), 63–87, 10.1002/med.20045.
31. [31] van den Broek, M., Visser, K., Allaart, C.F., Huizinga, T.W.J., Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol 13 (2013), 463–469, 10.1016/j.coph.2013.03.006.
32. [32] Anaya, J., Acceso a la atención en salud. En busca de la medicina personalizada y el sistema PS. Medicina (B Aires) 36 (2014), 9–12.
33. [33] Pirmohamed, M., Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin Pharmacol Ther 88 (2010), 862–866, 10.1038/clpt.2010.245.
34. [34] Parikh, N.I., Vasan, R.S., Assessing the clinical utility of biomarkers in medicine. Biomark Med 1 (2007), 419–436, 10.2217/17520363.1.3.419.
35. [35] Tektonidou, M.G., Ward, M.M., Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases. Arthritis Res Ther, 12, 2010, R179, 10.1186/ar3143.
36. [36] Daïen, C.I., Morel, J., Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm, 2014, 2014, 386148, 10.1155/2014/386148.
37. [37] Cui, J., Saevarsdottir, S., Thomson, B., Padyukov, L., van der Helm-van Mil, A.H.M., Nititham, J., et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62 (2010), 1849–1861, 10.1002/art.27457.
38. [38] Plant, D., Prajapati, R., Hyrich, K.L., Morgan, A.W., Wilson, A.G., Isaacs, J.D., et al. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 64 (2012), 665–670, 10.1002/art.33381.
39. [39] Plant, D., Bowes, J., Potter, C., Hyrich, K.L., Morgan, A.W., Wilson, A.G., et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 63 (2011), 645–653, 10.1002/art.30130.
40. [40] Wijbrandts, C.A., Dijkgraaf, M.G.W., Kraan, M.C., Vinkenoog, M., Smeets, T.J., Dinant, H., et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 67 (2008), 1139–1144, 10.1136/ard.2007.080440.
41. [41] Kayakabe, K., Kuroiwa, T., Sakurai, N., Ikeuchi, H., Kadiombo, A.T., Sakairi, T., et al. Interleukin-1β measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis. Rheumatology (Oxford) 51 (2012), 1639–1643, 10.1093/rheumatology/kes094.
42. [42] Chen, D.-Y., Chen, Y.-M., Chen, H.-H., Hsieh, C.-W., Lin, C.-C., Lan, J.-L., Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther, 13, 2011, R126, 10.1186/ar3431.
43. [43] Jamnitski, A., Bartelds, G.M., Nurmohamed, M.T., van Schouwenburg, P.A., van Schaardenburg, D., Stapel, S.O., et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 70 (2011), 284–288, 10.1136/ard.2010.135111.
44. [44] Kleinert, S., Tony, H.-P., Krause, A., Feuchtenberger, M., Wassenberg, S., Richter, C., et al. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study. Rheumatol Int 32 (2012), 2759–2767, 10.1007/s00296-011-2033-5.
45. [45] Burmester, G.R., Ferraccioli, G., Flipo, R.-M., Monteagudo-Sáez, I., Unnebrink, K., Kary, S., et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59 (2008), 32–41, 10.1002/art.23247.
46. [46] van der Heijde, D., Klareskog, L., Landewé, R., Bruyn, G.A.W., Cantagrel, A., Durez, P., et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56 (2007), 3928–3939, 10.1002/art.23141.
47. [47] Hyrich, K.L., Symmons, D.P.M., Watson, K.D., Silman, A.J., British Society for Rheumatology Biologics Register, Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Bi. Arthritis Rheum 54 (2006), 1786–1794, 10.1002/art.21830.
48. [48] Abhishek, A., Butt, S., Gadsby, K., Zhang, W., Deighton, C.M., Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol 16 (2010), 15–18, 10.1097/RHU.0b013e3181ca4a2a.
49. [49] Canhão, H., Rodrigues, A.M., Mourão, A.F., Martins, F., Santos, M.J., Canas-Silva, J., et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford) 51 (2012), 2020–2026, 10.1093/rheumatology/kes184.
50. [50] Saevarsdottir, S., Wedrén, S., Seddighzadeh, M., Bengtsson, C., Wesley, A., Lindblad, S., et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish rheumatology Reg. Arthritis Rheum 63 (2011), 26–36, 10.1002/art.27758.
51. [51] Klaasen, R., Wijbrandts, C.A., Gerlag, D.M., Tak, P.P., Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 63 (2011), 359–364, 10.1002/art.30136.
52. [52] Gremese, E., Carletto, A., Padovan, M., Atzeni, F., Raffeiner, B., Giardina, A.R., et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) 65 (2013), 94–100, 10.1002/acr.21768.
53. [53] Kristensen, L.E., Kapetanovic, M.C., Gülfe, A., Söderlin, M., Saxne, T., Geborek, P., Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the south Swedish arthritis treatment group register. Rheumatology (Oxford) 47 (2008), 495–499, 10.1093/rheumatology/ken002.
54. [54] Potter, C., Hyrich, K.L., Tracey, A., Lunt, M., Plant, D., Symmons, D.P.M., et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 68 (2009), 69–74, 10.1136/ard.2007.084715.
55. [55] Wang, J., Platt, A., Upmanyu, R., Germer, S., Lei, G., Rabe, C., et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open, 3, 2013, e003199, 10.1136/bmjopen-2013-003199.
56. [56] Yamanaka, H., Tanaka, Y., Inoue, E., Hoshi, D., Momohara, S., Hanami, K., et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 21 (2011), 122–133, 10.1007/s10165-010-0366-7.
57. [57] Leffers, H.C., Ostergaard, M., Glintborg, B., Krogh, N.S., Foged, H., Tarp, U., et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70 (2011), 1216–1222, 10.1136/ard.2010.140129.
58. [58] Ruyssen-Witrand, A., Rouanet, S., Combe, B., Dougados, M., Le Loët, X., Sibilia, J., et al. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 71 (2012), 875–877, 10.1136/annrheumdis-2011-200337.
59. [59] Quartuccio, L., Fabris, M., Pontarini, E., Salvin, S., Zabotti, A., Benucci, M., et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis 73 (2014), 716–721, 10.1136/annrheumdis-2012-202435.
60. [60] Sellam, J., Hendel-Chavez, H., Rouanet, S., Abbed, K., Combe, B., Le Loët, X., et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 63 (2011), 933–938, 10.1002/art.30233.
61. [61] Vital, E.M., Dass, S., Rawstron, A.C., Buch, M.H., Goëb, V., Henshaw, K., et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 62 (2010), 1273–1279, 10.1002/art.27359.
62. [62] Soliman, M.M., Hyrich, K.L., Lunt, M., Watson, K.D., Symmons, D.P.M., Ashcroft, D.M., et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology biologics register. J Rheumatol 39 (2012), 240–246, 10.3899/jrheum.110610.
63. [63] Maneiro, R.J., Salgado, E., Carmona, L., Gomez-Reino, J.J., Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum 43 (2013), 9–17, 10.1016/j.semarthrit.2012.11.007.
64. [64] Chatzidionysiou, K., Lie, E., Nasonov, E., Lukina, G., Hetland, M.L., Tarp, U., et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 70 (2011), 1575–1580, 10.1136/ard.2010.148759.
65. [65] Sarmiento-Monroy, J.C., Villota-Eraso, C., Mantilla, R., Factors associated with response to abatacept in rheumatoid arthritis: a systematic literature review. 10th Int Congr Autoimmun, 2016 [Abstract].
66. [66] Scarsi, M., Ziglioli, T., Airò, P., Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol 37 (2010), 911–916, 10.3899/jrheum.091176.
67. [67] Scarsi, M., Ziglioli, T., Airo', P., Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol 38 (2011), 2105–2111, 10.3899/jrheum.110386.
68. [68] Gottenberg, J.E., Ravaud, P., Cantagrel, A., Combe, B., Flipo, R.M., Schaeverbeke, T., et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the “Orencia and rheumatoid arthritis” registry. Ann Rheum Dis 71 (2012), 1815–1819, 10.1136/annrheumdis-2011-201109.
69. [69] Yazici Y, Moniz Reed D, Klem C, Rosenblatt L, Wu G, Kremer JM. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Clin Exp Rheumatol n.d.;29:494–9.
70. [70] Takahashi, N., Fujibayashi, T., Kida, D., Hirano, Y., Kato, T., Kato, D., et al. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. Rheumatol Int 35 (2015), 1707–1716, 10.1007/s00296-015-3283-4.
71. [71] Sokolove, J., Schiff, M., Fleischmann, R., Weinblatt, M.E., Connolly, S.E., Johnsen, A., et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis 75 (2016), 709–714, 10.1136/annrheumdis-2015-207942.
72. [72] Nüßlein, H.G., Alten, R., Galeazzi, M., Lorenz, H.-M., Nurmohamed, M.T., Bensen, W.G., et al. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord, 16, 2015, 176, 10.1186/s12891-015-0636-9.
73. [73] Cuppen, B.V.J., Welsing, P.M.J., Sprengers, J.J., Bijlsma, J.W.J., Marijnissen, A.C.A., van Laar, J.M., et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology (Oxford), 2015, 10.1093/rheumatology/kev421 [kev421].
74. [74] Lee, Y.H., Bang, H., Kim, D.J., How to establish clinical prediction models. Endocrinol Metab (Seoul, Korea) 31 (2016), 38–44, 10.3803/EnM.2016.31.1.38.
75. [75] Steyerberg EW, Moons KGM, Van Der Windt DA, Hayden JA, Perel P, Schroter S, et al. Guidelines and Guidance Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research n.d. doi: http://dx.doi.org/10.1371/journal.pmed.1001381.
76. [76] Collins, G.S., Reitsma, J.B., Altman, D.G., Moons, K.G.M., Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Eur Urol 67 (2015), 1142–1151, 10.1016/j.eururo.2014.11.025.
77. [77] Lee, Y.-H., Bang, H., Kim, D.J., How to establish clinical prediction models. Endocrinol Metab 31 (2016), 38–44, 10.3803/EnM.2016.31.1.38.
78. [78] Socioeconomic status. The relationship with health and autoimmune diseases n.d. http://ac.els-cdn.com.ez.urosario.edu.co/S1568997214000044/1-s2.0-S1568997214000044-main.pdf?_tid=7403c44e-6d35-11e5-8dd4-00000aab0f02&acdnat=1444251385_316cae842b612f6e88e8ff654a6c91e1 [accessed October 7, 2015].
79. [79] Deshmukh, H.A., Maiti, A.K., Kim-Howard, X.R., Rojas-Villarraga, A., Guthridge, J.M., Anaya, J.-M., et al. Evaluation of 19 autoimmune disease-associated loci with rheumatoid arthritis in a Colombian population: evidence for replication and gene–gene interaction. J Rheumatol 38 (2011), 1866–1870, 10.3899/jrheum.110199.
80. [80] Rojas-Villarraga, A., Diaz, F.J., Calvo-Páramo, E., Salazar, J.C., Iglesias-Gamarra, A., Mantilla, R.D., et al. Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. J Autoimmun 32 (2009), 64–69, 10.1016/j.jaut.2008.11.004.
81. [81] Diaz, F.J., Rojas-Villarraga, A., Salazar, J.C., Iglesias-Gamarra, A., Mantilla, R.D., Anaya, J.-M., Anti-CCP antibodies are associated with early age at onset in patients with rheumatoid arthritis. Joint Bone Spine 78 (2011), 175–178, 10.1016/j.jbspin.2010.07.014.
82. [82] Palomino-Morales, R.J., Rojas-Villarraga, A., González, C.I., Ramírez, G., Anaya, J.-M., Martín, J., STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians. Genes Immun 9 (2008), 379–382, 10.1038/gene.2008.30.
83. [83] Delgado-Vega, A.M., Anaya, J.-M., Meta-analysis of HLA-DRB1 polymorphism in Latin American patients with rheumatoid arthritis. Autoimmun Rev 6 (2007), 402–408, 10.1016/j.autrev.2006.11.004.
84. [84] Malandrino, N., Smith, R.J., Personalized medicine in diabetes. Clin Chem 57 (2011), 231–240, 10.1373/clinchem.2010.156901.
85. [85] Szablewski, L., Role of immune system in type 1 diabetes mellitus pathogenesis. Int Immunopharmacol 22 (2014), 182–191, 10.1016/j.intimp.2014.06.033.
86. [86] Winter, W.E., Schatz, D.A., Autoimmune markers in diabetes. Clin Chem 57 (2011), 168–175, 10.1373/clinchem.2010.148205.
87. [87] De Ferranti, S.D., De Boer, I.H., Fonseca, V., Fox, C.S., Golden, S.H., Lavie, C.J., et al. AHA/ADA scientific statement type 1 diabetes mellitus and cardiovascular disease. Circulation 130 (2014), 1110–1130, 10.1161/CIR.0000000000000034.
88. [88] Bonifacio, E., Ziegler, A.G., Advances in the prediction and natural history of type 1 diabetes. Endocrinol Metab Clin North Am 39 (2010), 513–525, 10.1016/j.ecl.2010.05.007.
89. [89] Rojas-Villarraga, A., Botello-Corzo, D., Anaya, J.-M., HLA-class II in Latin American patients with type 1 diabetes. Autoimmun Rev 9 (2010), 666–673, 10.1016/j.autrev.2010.05.016.
90. [90] Noble, J.A., Valdes, A.M., Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep 11 (2011), 533–542, 10.1007/s11892-011-0223-x.
91. [91] Anaya, J.-M., Castiblanco, J., Tobón, G.J., García, J., Abad, V., Cuervo, H., et al. Familial clustering of autoimmune diseases in patients with type 1 diabetes mellitus. J Autoimmun 26 (2006), 208–214, 10.1016/j.jaut.2006.01.001.
92. [92] Watkins, R.A., Evans-Molina, C., Blum, J.S., Dimeglio, L.A., Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. Transl Res 164 (2014), 110–121, 10.1016/j.trsl.2014.02.004.
93. [93] Bernal, O., Barbosa, S., Challenges of the right to health in the Colombian model. Salud Publica Mex 57 (2015), 433–440.
94. [94] Lichstein PR. Returning to the Bedside: Notes From a Clinical Educator. N C Med J n.d.;76:174–9. doi: 10.18043/ncm.76.3.174.
95. [95] Shay LA, Lafata JE. Understanding patient perceptions of shared decision making n.d. doi: http://dx.doi.org/10.1016/j.pec.2014.07.017.
96. [96] Lavallee, D.C., Chenok, K.E., Love, R.M., Petersen, C., Holve, E., Segal, C.D., et al. Incorporating patient-reported outcomes into health care to engage patients and enhance care. Health Aff 35 (2016), 575–582, 10.1377/hlthaff.2015.1362.
97. [97] Hirshleifer, J., The private and social value of information and the reward to inventive activity. Am Econ Rev 61 (1971), 561–574, 10.2307/1811850.
98. [98] Bardey, D., De Donder, P., Genetic testing with primary prevention and moral hazard. J Health Econ 32 (2013), 768–779, 10.1016/j.jhealeco.2013.04.008.
99. [99] Barigozzi, F., Henriet, D., Genetic information: comparing alternative regulatory approaches when prevention matters. J Public Econ Theory 13 (2011), 23–46, 10.1111/j.1467-9779.2009.01491.x.
100. [100] Crocker, K., Snow, A., The theory of risk classification. Dionne, G., (eds.) Handb. Insur., 2013, Springer New York, New York, NY, 10.1007/978-1-4614-0155-1.
101. [101] Castiblanco, J., Arcos-Burgos, M., Anaya, J.-M., What is next after the genes for autoimmunity?. BMC Med, 11, 2013, 197, 10.1186/1741-7015-11-197.
102. [102] Simmons, K.M., Michels, A.W., Type 1 diabetes: a predictable disease. World J Diabetes 6 (2015), 380–390, 10.4239/wjd.v6.i3.380.
103. [103] Gerlag, D.M., Norris, J.M., Tak, P.P., RA: from risk factors and pathogenesis to prevention. Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment. Rheumatology, 55, 2015, 10.1093/rheumatology/kev347 [kev347].
104. [104] Antico, A., Tampoia, M., Tozzoli, R., Bizzaro, N., Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 12 (2012), 127–136, 10.1016/j.autrev.2012.07.007.
105. [105] Gravano, D.M., Hoyer, K.K., Promotion and prevention of autoimmune disease by CD8 + T cells. J Autoimmun 45 (2013), 68–79, 10.1016/j.jaut.2013.06.004.
106. [106] Holick, M.F., Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80 (2004), 1678S–1688S.
107. [107] Klareskog, L., Gregersen, P.K., Huizinga, T.W.J., Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis 69 (2010), 2062–2066, 10.1136/ard.2010.142109.
108. [108] Özdemir, Ö., Any role for probiotics in the therapy or prevention of autoimmune diseases? Up-to-date review. J Complement Integr Med, 10, 2013, 10.1515/jcim-2012-0054.
109. [109] Rose, N.R., Prediction and prevention of autoimmune disease in the 21st century: a review and preview. Am J Epidemiol 183 (2016), 403–406, 10.1093/aje/kwv292.
110. [110] Yang, C.-Y., Leung, P.S.C., Adamopoulos, I.E., Gershwin, M.E., The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol 45 (2013), 217–226, 10.1007/s12016-013-8361-3.
111. [111] Delvin, E., Souberbielle, J.-C., Viard, J.-P., Salle, B., Role of vitamin D in acquired immune and autoimmune diseases. Crit Rev Clin Lab Sci 51 (2014), 232–247, 10.3109/10408363.2014.901291.
112. [112] Holick, M.F., Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J 98 (2005), 1024–1027, 10.1097/01.SMJ.0000140865.32054.DB.
113. [113] Bykerk, V.P., Strategies to prevent rheumatoid arthritis in high-risk patients. Curr Opin Rheumatol 23 (2011), 179–184, 10.1097/BOR.0b013e32834379ee.
114. [114] de Hair, M.J.H., Landewé, R.B.M., van de Sande, M.G.H., van Schaardenburg, D., van Baarsen, L.G.M., Gerlag, D.M., et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis 72 (2013), 1654–1658, 10.1136/annrheumdis-2012-202254.
115. [115] Hunt, L., Emery, P., Defining populations at risk of rheumatoid arthritis: the first steps to prevention. Nat Rev Rheumatol 10 (2014), 521–530, 10.1038/nrrheum.2014.82.
116. [116] Karlson, E.W., Ding, B., Keenan, B.T., Liao, K., Costenbader, K.H., Klareskog, L., et al. Association of environmental and genetic factors and gene–environment interactions with risk of developing rheumatoid arthritis. Arthritis Care Res (Hoboken) 65 (2013), 1147–1156, 10.1002/acr.22005.
117. [117] Kostoglou-Athanassiou, I., Athanassiou, P., Lyraki, A., Raftakis, I., Antoniadis, C., Vitamin D and rheumatoid arthritis. Ther Adv Endocrinol Metab 3 (2012), 181–187, 10.1177/2042018812471070.
118. [118] Lahiri, M., Morgan, C., Symmons, D.P.M., Bruce, I.N., Modifiable risk factors for RA: prevention, better than cure?. Rheumatology (Oxford) 51 (2012), 499–512, 10.1093/rheumatology/ker299.
119. [119] Mankia, K., Emery, P., Is localized autoimmunity the trigger for rheumatoid arthritis? Unravelling new targets for prevention. Discov Med 20 (2015), 129–135.
120. [120] Mankia, K., Emery, P., Review: preclinical rheumatoid arthritis: progress toward prevention. Arthritis Rheumatol (Hoboken, NJ) 68 (2016), 779–788, 10.1002/art.39603.
121. [121] Novotny, F., Haeny, S., Hudelson, P., Escher, M., Finckh, A., Primary prevention of rheumatoid arthritis: a qualitative study in a high-risk population. Joint Bone Spine 80 (2013), 673–674, 10.1016/j.jbspin.2013.05.005.
122. [122] Naranjo, A., Bilbao, A., Erausquin, C., Ojeda, S., Francisco, F.M., Rúa-Figueroa, I., et al. Results of a specific smoking cessation program for patients with arthritis in a rheumatology clinic. Rheumatol Int 34 (2014), 93–99, 10.1007/s00296-013-2851-8.
123. [123] van Beers-Tas, M.H., Turk, S.A., van Schaardenburg, D., How does established rheumatoid arthritis develop, and are there possibilities for prevention?. Best Pract Res Clin Rheumatol 29 (2015), 527–542, 10.1016/j.berh.2015.09.001.
124. [124] Walsh, C.A.E., Conaghan, P.G., Smoking: a preventable cause of rheumatoid arthritis. Practitioner, 255, 2011, 5.
125. [125] Herzinger, T., Plewig, G., Röcken, M., Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 50 (2004), 3045–3046, 10.1002/art.20426.
126. [126] Horowitz, D.M., Furie, R.A., Abetimus sodium: a medication for the prevention of lupus nephritis flares. Expert Opin Pharmacother 10 (2009), 1501–1507, 10.1517/14656560902946419.
127. [127] Ilchyshyn, L., Hawk, J.L.M., Millard, T.P., Photoprotection: does it work?. Lupus 17 (2008), 705–707, 10.1177/0961203308093924.
128. [128] Robinson, A.B., Tangpricha, V., Yow, E., Gurion, R., Schanberg, L.E., McComsey, G.A., Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an atherosclerosis prevention in pediatric lupus erythematosus (APPLE) substudy. Lupus Sci Med, 1, 2014, e000037, 10.1136/lupus-2014-000037.
129. [129] Tang, C., Godfrey, T., Stawell, R., Nikpour, M., Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J 42 (2012), 968–978, 10.1111/j.1445-5994.2012.02886.x.
130. [130] Vilá, L.M., Mayor, A.M., Valentín, A.H., Rodríguez, S.I., Reyes, M.L., Acosta, E., et al. Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. P R Health Sci J 18 (1999), 89–94.
131. [131] D'Aurizio, F., Villalta, D., Metus, P., Doretto, P., Tozzoli, R., Is vitamin D a player or not in the pathophysiology of autoimmune thyroid diseases?. Autoimmun Rev 14 (2015), 363–369, 10.1016/j.autrev.2014.10.008.
132. [132] Laurberg, P., Andersen, S., Pedersen, I.B., Knudsen, N., Carlé, A., Prevention of autoimmune hypothyroidism by modifying iodine intake and the use of tobacco and alcohol is manoeuvring between Scylla and Charybdis. Hormones (Athens) 12 (2013), 30–38.
133. [133] Carlé, A., Bülow Pedersen, I., Knudsen, N., Perrild, H., Ovesen, L., Rasmussen, L.B., et al. Graves' hyperthyroidism and moderate alcohol consumption: evidence for disease prevention. Clin Endocrinol (Oxf) 79 (2013), 111–119, 10.1111/cen.12106.
134. [134] Jaberi-Douraki, M., Liu, S.W.S., Pietropaolo, M., Khadra, A., Autoimmune responses in T1DM: quantitative methods to understand onset, progression, and prevention of disease. Pediatr Diabetes 15 (2014), 162–174, 10.1111/pedi.12148.
135. [135] Sedimbi, S.K., Sanjeevi, C.B., Prevention of beta-cell destruction in autoimmune diabetes: current approaches and future prospects. Adv Exp Med Biol 654 (2010), 611–626, 10.1007/978-90-481-3271-3_26.
136. [136] Simmons, K., Michels, A.W., Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease. Rheum Dis Clin North Am 40 (2014), 797–811, 10.1016/j.rdc.2014.07.008.
137. [137] Todd, J.A., Knip, M., Mathieu, C., Strategies for the prevention of autoimmune type 1 diabetes. Diabet Med 28 (2011), 1141–1143, 10.1111/j.1464-5491.2011.03400.x.
138. [138] Pender, M.P., Wolfe, N.P., Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects. Intern Med J 32 (2002), 554–563.
139. [139] Speer, G., Impact of vitamin D in neurological diseases and neurorehabilitation: from dementia to multiple sclerosis. Part I: the role of vitamin D in the prevention and treatment of multiple sclerosis. Ideggyógyászati Szle 66 (2013), 293–303.
140. [140] Ganesh, A., Apel, S., Metz, L., Patten, S., The case for vitamin D supplementation in multiple sclerosis. Mult Scler Relat Disord 2 (2013), 281–306, 10.1016/j.msard.2012.12.008.
141. [141] Bertero, M.T., Primary prevention in antiphospholipid antibody carriers. Lupus 21 (2012), 751–754, 10.1177/0961203312445229.
142. [142] Finazzi, G., Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders. Lupus 21 (2012), 747–750, 10.1177/0961203312437440.
143. [143] Mecacci, F., Simeone, S., Rambaldi, M.P., Serena, C., Ottanelli, S., Marchetti, G., et al. Prediction and prevention of preeclampsia in autoimmune disease. Pregnancy Hypertens, 1, 2011, 244, 10.1016/j.preghy.2011.08.011.
144. [144] Capriati, T., Francavilla, R., Castellaneta, S., Ferretti, F., Diamanti, A., Impact of the birth's season on the development of celiac disease in Italy. Eur J Pediatr 174 (2015), 1657–1663, 10.1007/s00431-015-2589-2.
145. [145] Czaja, A.J., Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther 39 (2014), 385–406, 10.1111/apt.12592.
146. [146] Nancy, A.-L., Yehuda, S., Prediction and prevention of autoimmune skin disorders. Arch Dermatol Res 301 (2009), 57–64, 10.1007/s00403-008-0889-3.
147. [147] Smyk, D.S., Orfanidou, T., Invernizzi, P., Bogdanos, D.P., Lenzi, M., Vitamin D in autoimmune liver disease. Clin Res Hepatol Gastroenterol 37 (2013), 535–545, 10.1016/j.clinre.2013.05.016.
148. [148] Bar-Dayan, Y., Gershwin, M.E., Levi, Y., Amital, H., Shoenfeld, Y., Primary biliary cirrhosis. Is (and how much of) the pathology preventible?. Immunol Res 18 (1998), 117–123, 10.1007/BF02788754.
149. [149] Shi, J., Wu, C., Lin, Y., Chen, Y.-X., Zhu, L., Xie, W., Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 101 (2006), 1529–1538, 10.1111/j.1572-0241.2006.00634.x.